Results 21 to 30 of about 798 (156)

Increased cell killing effect in neutron capture enhanced proton beam therapy [PDF]

open access: yesScientific Reports
Thermal neutrons generated in the body during proton beam therapy (PBT) can be used to cause boron neutron capture reactions and have recently been proposed as neutron capture enhanced PBT (NCEPBT).
Shintaro Shiba   +7 more
doaj   +2 more sources

ASSESSMENT OF THE EFFECT OF BORON NEUTRON CAPTURE THERAPY ON TUMOR CELL LINES AND PRIMARY EMBRYONIC CELL CULTURE

open access: yesСибирский онкологический журнал, 2021
Introduction. Boron neutron capture therapy (bnct) is a promising method for treating tumors, in particular, infiltrative malignant tumors, due to the selective destruction of tumor cells without damaging the surrounding normal tissues.
V. V. Kanygin   +6 more
doaj   +1 more source

Dose-Dependent Suppression of Human Glioblastoma Xenograft Growth by Accelerator-Based Boron Neutron Capture Therapy with Simultaneous Use of Two Boron-Containing Compounds

open access: yesBiology, 2021
(1) Background: Developments in accelerator-based neutron sources moved boron neutron capture therapy (BNCT) to the next phase, where new neutron radiation parameters had to be studied for the treatment of cancers, including brain tumors.
Vladimir Kanygin   +11 more
doaj   +1 more source

Boron Neutron Capture Therapy - A Literature Review [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2016
Boron Neutron Capture Therapy (BNCT) is a radiation science which is emerging as a hopeful tool in treating cancer, by selectively concentrating boron compounds in tumour cells and then subjecting the tumour cells to epithermal neutron beam radiation ...
Kavitaa Nedunchezhian   +3 more
doaj   +1 more source

Correlation between L‐amino acid transporter 1 expression and 4‐borono‐2‐18F‐fluoro‐phenylalanine accumulation in humans

open access: yesCancer Medicine, 2023
Background The correlation between L‐type amino acid transporter 1 (LAT1) expression and 4‐borono‐2‐18F‐fluoro‐phenylalanine (18F‐FBPA) accumulation in humans remains unclear.
Tairo Kashihara   +9 more
doaj   +1 more source

Nanostructured boron agents for boron neutron capture therapy: a review of recent patents

open access: yesMedical Review, 2023
Boron neutron capture therapy (BNCT) is a potential radiation therapy modality for cancer, and tumor-targeted stable boron-10 (10B) delivery agents are an important component of BNCT. Currently, two low-molecular-weight boron-containing compounds, sodium
Zhang Xiyin   +3 more
doaj   +1 more source

Boron Vehiculating Nanosystems for Neutron Capture Therapy in Cancer Treatment

open access: yesCells, 2022
Boron neutron capture therapy is a low-invasive cancer therapy based on the neutron fission process that occurs upon thermal neutron irradiation of 10B-containing compounds; this process causes the release of alpha particles that selectively damage ...
Giorgia Ailuno   +7 more
doaj   +1 more source

Construction of targeted 10B delivery agents and their uptake in gastric and pancreatic cancer cells

open access: yesFrontiers in Oncology, 2023
Boron Neutron Capture Therapy (BNCT) is a new binary radiation therapy for tumor tissue, which kills tumor cells with neutron capture reaction. Boron neutron capture therapy has become a technical means for glioma, melanoma, and other diseases has been ...
Song Wang   +13 more
doaj   +1 more source

Synthesis and Characterization of Gd-Functionalized B4C Nanoparticles for BNCT Applications

open access: yesLife, 2023
Inorganic nanoparticles of boron-rich compounds represent an attractive alternative to boron-containing molecules, such as boronophenylalanine or boranes, for BNCT applications. This work describes the synthesis and biological activity of multifunctional
Agostina Vitali   +9 more
doaj   +1 more source

Water-Soluble closo-Docecaborate-Containing Pteroyl Derivatives Targeting Folate Receptor-Positive Tumors for Boron Neutron Capture Therapy

open access: yesCells, 2020
Water-soluble pteroyl-closo-dodecaborate conjugates (PBCs 1–4), were developed as folate receptor (FRα) targeting boron carriers for boron neutron capture therapy (BNCT).
Fumiko Nakagawa   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy